A phase I/II trial of pazopanib alternating with bevacizumab in treatment-naïve metastatic clear cell renal cell carcinoma (CCRCC) patients: Phase I results.

Saby George,Laurie Herbst,Marcus Sikorski,Ann Marie DiRaddo,Gissou Azabdaftari,Charles Roche,Eric Kauffman,Qiang Li,Thomas Schwaab,Ellis G. Levine,Roberto Pili,Gurkamal S. Chatta,Leonard Joseph Appleman,Adrienne Groman,Rahul Atul Parikh,Alan D. Hutson

A phase I/II trial of pazopanib alternating with bevacizumab in treatment-naïve metastatic clear cell renal cell carcinoma (CCRCC) patients: Phase I results.

2019

Saby George
Laurie Herbst
Marcus Sikorski
Ann Marie DiRaddo
Gissou Azabdaftari
Charles Roche
Eric Kauffman
Qiang Li
Thomas Schwaab
Ellis G. Levine
Roberto Pili
Gurkamal S. Chatta
Leonard Joseph Appleman
Adrienne Groman
Rahul Atul Parikh
Alan D. Hutson

561Background: Pazopanib as single agent and bevacizumab plus interferon were approved for use in metastatic RCC (MRCC) based on their ability to modulate the vasculature and prolong progression fr...

Keywords:

Bevacizumab
Oncology
Pathology
Clear cell renal cell carcinoma
Pazopanib
Internal medicine
Medicine
single agent
phase i ii
Cancer research
Interferon
therapy naive

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations